BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
FDA approves Wegovy pill for weight loss - 2Getting through a Lifelong Change: Individual Examples of overcoming adversity
- 3Step by step instructions to Think about Disc Rates Across Various Banks
- 4A rare whale is having an encouraging season for births. Scientists warn it might still go extinct
- 5Esteem Stuffed Gaming Workstations to Consider
- Israel says 40 Hezbollah members killed as forces advance in Lebanon
- Hamas hands over another body in the Gaza Strip
- Supportive Tips On Home loans For First-Time Home Purchasers
- Instructions to Expand Your Smash 1500's Presentation: Tips and Deceives
- Blue Origin launches huge rocket carrying twin NASA spacecraft to Mars
- Solar storms can trigger auroras on Earth. This star’s explosion could destroy a planet’s atmosphere
- Mummified cheetahs found in Saudi caves shed light on lost populations
- Whale stranded off Germany for days free again
- NASA study shows how satellite 'light pollution' hinders space telescopes
